SCHEMBL21628879

SCHEMBL21628879

NC(=O)c1cnc(Oc2ccc(C(F)(C(F)(F)F)C(F)(F)F)cc2)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
MAOB P27338 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
CHEK2 O96017 3/20 0.39
PARP10 Q53GL7 2/20 0.38
LTA4H P09960 4/20 0.38
KCNH2 Q12809 3/20 0.38
HPGDS O60760 1/20 0.38
PTGER4 P35408 1/20 0.38
ALDH1A1 P00352 1/20 0.37
KMT2A Q03164 1/20 0.37
PARP15 Q460N3 1/20 0.37
PARP14 Q460N5 1/20 0.37
PARP16 Q8N5Y8 1/20 0.37
PARP11 Q9NR21 1/20 0.37
PARP4 Q9UKK3 1/20 0.37
KDR P35968 1/20 0.36
FLT3 P36888 1/20 0.36
ICAM1 P05362 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21656911 0.90 SMN1; SMN2 (0.41) SMN1; SMN2MAOBKDM4EMAPTCHEK2
SCHEMBL29920878 0.90 SMN1; SMN2 (0.41) SMN1; SMN2MAOBKDM4EMAPTCHEK2
SCHEMBL21628728 0.90 SMN1; SMN2 (0.48) SMN1; SMN2MAOBKDM4EMAPTCHEK2
SCHEMBL21628893 0.89 PTGER4 (0.45) SMN1; SMN2LTA4HKCNH2PTGER4
SCHEMBL21628486 0.88 SMN1; SMN2 (0.40) SMN1; SMN2MAOBKDM4EMAPTCHEK2
SCHEMBL21628610 0.87 SMN1; SMN2 (0.39) SMN1; SMN2MAOBKDM4EMAPTCHEK2
SCHEMBL21628769 0.86 ICAM1 (0.44) SMN1; SMN2KDM4EMAPTPARP10HPGDS
SCHEMBL21628802 0.85 HDAC6 (0.44) PTGER4
SCHEMBL21628867 0.85 LMNA (0.49) SMN1; SMN2MAOBKDM4EMAPTPTGER4
SCHEMBL21628549 0.84 SMN1; SMN2 (0.41) SMN1; SMN2PTGER4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600696-B2 Aromatic compounds Xeniopro GmbH (DE) 2026-04-14 US disclosed
US-20230406814-A2 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2023-12-21 US disclosed
US-20230150923-A1 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2023-05-18 US disclosed
US-11591289-B2 Aromatic compounds Xeniopro GmbH (DE) 2023-02-28 US disclosed
US-11591289-B2 Aromatic compounds Xeniopro GmbH (DE) 2023-02-28 US disclosed
US-20220348535-A2 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2022-11-03 US disclosed
US-20210107863-A2 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2021-04-15 US disclosed
US-20200031763-A1 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2020-01-30 US disclosed
US-20200031763-A1 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150923-A1 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK SMN1; SMN2 796/4885MAOB 2110/4885KDM4E 143/4885
US-20220348535-A2 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK SMN1; SMN2 796/4885MAOB 2110/4885KDM4E 143/4885
US-11591289-B2 Aromatic compounds AHR, TYR, MUSK SMN1; SMN2 1107/4885MAOB 2399/4885KDM4E 152/4885
US-20210107863-A2 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK SMN1; SMN2 796/4885MAOB 2110/4885KDM4E 143/4885
US-12600696-B2 Aromatic compounds CCR1, CCRL2, AHR SMN1; SMN2 919/4885MAOB 1042/4885KDM4E 1660/4885
US-20230406814-A2 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK SMN1; SMN2 796/4885MAOB 2110/4885KDM4E 143/4885
US-20200031763-A1 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK SMN1; SMN2 796/4885MAOB 2110/4885KDM4E 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.